Drug Profile
Research programme: vaccines - Beijing Minhai Biotechnology
Alternative Names: DTaP-Hib-sIPV combined vaccine - Beijing Minhai Biotechnology; EV71 vaccine - Beijing Minhai Biotechnology; H1N1 influenza vaccine - Beijing Minhai Biotechnology; H7N9 influenza vaccine - Beijing Minhai Biotechnology; Herpes simplex vaccine - Beijing Minhai Biotechnology; Human papillomavirus vaccine quadrivalent - Beijing Minhai Biotechnology; Meningococcal vaccine group B - Beijing Minhai Biotechnology; MR and Varicella vaccine - Beijing Minhai Biotechnology; Mumps vaccine - Beijing Minhai Biotechnology; Rotavirus vaccine 5-valent - Beijing Minhai Biotechnology; Varicella vaccine - Beijing Minhai Biotechnology; Zoster vaccine - Beijing Minhai BiotechnologyLatest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Beijing Minhai Biotechnology
- Class Bacterial vaccines; Mumps vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diphtheria; Enterovirus A infections; Haemophilus infections; Herpes simplex virus infections; Human papillomavirus infections; Influenza A virus H1N1 subtype; Influenza A virus H7N9 subtype; Measles; Meningococcal group B infections; Mumps; Pertussis; Poliomyelitis; Rotavirus infections; Rubella; Tetanus; Varicella zoster virus infections
Most Recent Events
- 24 Aug 2023 Preclinical development is ongoing for Diphtheria in China
- 24 Aug 2023 Preclinical development is ongoing for Enterovirus A infections in China
- 24 Aug 2023 Preclinical development is ongoing for Haemophilus-infections in China